Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Change in Receivables (2018 - 2025)

Arcturus Therapeutics Holdings (ARCT) has disclosed Change in Receivables for 8 consecutive years, with -$2.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Receivables rose 90.9% year-over-year to -$2.4 million, compared with a TTM value of $1.6 million through Dec 2025, up 105.66%, and an annual FY2025 reading of $1.6 million, up 105.66% over the prior year.
  • Change in Receivables was -$2.4 million for Q4 2025 at Arcturus Therapeutics Holdings, up from -$9.3 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $89.7 million in Q1 2023 and bottomed at -$89.7 million in Q2 2023.
  • Average Change in Receivables over 5 years is $171950.0, with a median of -$133000.0 recorded in 2021.
  • Peak annual rise in Change in Receivables hit 27591.05% in 2023, while the deepest fall reached 6110.8% in 2023.
  • Year by year, Change in Receivables stood at $1.4 million in 2021, then plummeted by 46.75% to $720000.0 in 2022, then tumbled by 955.0% to -$6.2 million in 2023, then crashed by 326.01% to -$26.2 million in 2024, then soared by 90.9% to -$2.4 million in 2025.
  • Business Quant data shows Change in Receivables for ARCT at -$2.4 million in Q4 2025, -$9.3 million in Q3 2025, and $2.6 million in Q2 2025.